Acute telogen effluvium (ATE) is a non-scarring alopecia characterized by significant hair shedding caused by disruption of the hair growth-rest cycle. 1 in 10 people experience ATE as a consequence of symptomatic SARS-CoV-2.

Of the hair regrowth treatments that exist, less than 12 percent are considered natural.

This study will test a natural, mycelium-based hair growth treatment against its synthetic equivalents on its ability to stimulate growth.